DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are being investigated in two ongoing, phase 3, randomized, double-blind, placebo-con...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies-Gow, Andrew, Ponnarambil, Sandhia, Downie, John, Bowen, Karin, Hellqvist, Åsa, Colice, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576983/
https://www.ncbi.nlm.nih.gov/pubmed/33087119
http://dx.doi.org/10.1186/s12931-020-01541-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576983/
https://www.ncbi.nlm.nih.gov/pubmed/33087119
http://dx.doi.org/10.1186/s12931-020-01541-7

Ejemplares similares